P4L adoption framework · Version 1.0
Healthcare innovation often fails at the absorption layer.
Short answer: Evidence may establish that an innovation is credible for a defined use. Adoption still depends on whether an institution can interpret it, decide, integrate it into workflow, fund it, earn trust, complete delivery, and learn from real outcomes.
Boundary: The P4L Institutional Absorption Test is a strategic framework. It does not establish clinical effectiveness, regulatory status, coverage, procurement eligibility, or expected return.
The gap
A scientific milestone is not an operating pathway.
Selected, funded, accepted, cleared, authorized, purchased, installed, used, completed, effective, and scaled describe different transitions. Responsible adoption makes those transitions visible instead of treating the first milestone as proof of the last.
Institutional Absorption Test
Eight questions before declaring adoption.
1. Evidence fit
Does the evidence match the intended use, population, setting, comparator, and claim?
2. Decision owner
Who has authority to choose, approve, fund, implement, stop, or revise the pathway?
3. Clinical meaning
Will the information change an appropriate action, or only add data, alerts, and burden?
4. Workflow
Who receives the signal, acts, escalates, documents, coordinates, and closes the loop?
5. Economics
Who pays, who benefits, which costs move, and do incentives support completion and quality?
6. Trust and claims
Can each stakeholder see the evidence, uncertainty, intended use, disclosure, and correction path?
7. Access and capability
Can the people and organizations expected to use the pathway actually reach, understand, and operate it?
8. Measurement
Are delivery, use, completion, functional, clinical, operational, economic, and equity outcomes distinguished?
What the framework changes
Instead of asking only whether an innovation is promising, the absorption test asks which institutional decision must move next and which conditions make that decision executable. It also exposes where communications is an operating dependency: meaning, trust, stakeholder alignment, escalation, and learning can fail even when the underlying science is sound.
Public application
The August 2026 P4L Evidence Note applies this distinction to current CMS, FDA, and ARPA-H developments. It separates program and participant status from demonstrated effectiveness and identifies workflow, evidence, and adoption questions that remain open.